ClinicalTrials.gg
TerminatedNCT04615949Updated Apr 21, 2026Results posted

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

A Phase 2/3 interventional study of Cannabidiol, pharmaceutically produced with < 5 ppm THC and Placebo in COVID-19, Cardiovascular Diseases and Cardiovascular Risk Factor, sponsored by Cardiol Therapeutics Inc.. Terminated at 20 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Cardiol Therapeutics Inc. · Phase 2/3, Interventional, and Prevention

Why this study was terminated
The changing nature of COVID-19 including a more vaccinated population, increasing natural population immunity, milder variants and other related factors has meant that it is no longer realistic to recruit the patients in a reasonable time frame.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 317 studies in COVID-19 with a site in Brazil — 20 open to participants now, 28 under way, 9 of them phase 3. COVID-19 · Brazil.

Enrollment
184th of 263
90 · median 205
Started
2021
with 102 others
Phase 2/3
34 of 317
none open now
Registered
133rd of 317
by date

Among the 317 studies in COVID-19 with a site in Brazil, this one is the 184th largest by enrollment of the 263 interventional ones that give a count, is one of 103 that started in 2021, is one of 34 in phase 2/3, and was the 133rd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

20 of the 317 studies in COVID-19 with a site in Brazil are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in COVID-19 with a site in Brazil, or all of them as a file.
02

Study summary

Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.

Read the detailed description

Multi-center, double-blind, randomized, placebo-controlled, parallel group design. 1:1 randomization.

Screening (Day 0-1): Patients hospitalized for COVID-19 within the past 24 hours will be screened. If patient consent can be obtained, baseline assessments will be carried out: Physical examination (including vital signs), ECG including QTc interval assessment, echocardiogram to measure left-ventricular ejection fraction (LVEF), chest X-ray, local laboratory (including CBC, AST/ALT, alkaline phosphatase, bilirubin, creatinine/eGFR, INR, pregnancy test (in women with child-bearing potential only), lymphocyte count and LDH. A C-SSRS will also be completed. Frozen plasma will be retained for central analysis of CardiolRx™ levels, hs-troponin, NT-proBNP, D-dimer as well as inflammatory markers (hs-CRP, ferritin, TNF-alpha, IL-1 beta, IL-6, IL-10).

If all eligibility criteria are met, the patient will be randomized to either CardiolRx™ or placebo.

Study treatment will be initiated immediately after all baseline assessments have been completed and the patient is randomized (Day1). Oral administration is as follows:

  • Day 1 and Day 2: Initial dose: 2.5 mg/kg of body weight b.i.d. with food: CardiolRx™ or placebo
  • Day 3 and Day 4: Increased to 5 mg/kg of body weight b.i.d. with food: CardiolRx™ or placebo
  • Day 5 to Day 28: Increased to 7.5 mg/kg of body weight b.i.d. with food: CardiolRx™ or placebo For the first 7 days and on Day 10, an ECG will be recorded 4 hours post morning dose with QTc intervals measured. If the QTc interval is >500 msec or an increase of > 60 msec from baseline is observed, the study medication must be stopped immediately.

If the next higher dose is not tolerated for other reasons, the dose will be reduced to the previous tolerated dose. The highest tolerated dose will be administered until Day 28.

If the patient is discharged before Day 10, the assessments up to Day 10 will be carried out as home visits. After Day 10, all remaining scheduled assessments will be carried out during out-patient visits (or home visits, if out-patient visits are not feasible).

In addition to prolongation of the QTc intervals, careful observation is required to detect other Adverse Drug Reactions (ADRs) and Drug-Drug Interactions (DDIs). Because CardiolRx™, may inhibit the metabolism of other drugs, new symptoms may represent toxicity from a concomitant medication that had previously been well tolerated.

A nasopharyngeal swab will also be done every day until Day 7 and on Day 14 to test for presence of the SARS-CoV-2 virus.

After Day 7, assessments will be carried out on a weekly basis except for as noted above on Day 10.

Frozen plasma will be retained for central analysis of CardiolRx™ levels, hs-troponin, NT-proBNP, D-dimer, inflammatory markers (hs-CRP, ferritin, TNF-alpha, IL-1 beta, IL-6, IL-10) and additional parameters of interest every two days until Day 7 as well as on day 28.

The assessments on Day 28 include the following: Physical examination (including vital signs), ECG (recorded 4 hours post morning dose for measurement of QTc interval), echocardiogram to measure LVEF, chest X-ray, local laboratory assessments, including CBC, AST/ALT, alkaline phosphatase, bilirubin, creatinine/eGFR, INR, lymphocyte count and LDH. In addition, a C-SSRS will be completed and the patient will be asked to answer a PICQ.

Further follow-up visits are scheduled for Day 45 and Day 60 post randomization. These include a clinical assessment (including vital signs) as well as the completion of the PICQ (PICQ on Day 60 only). Any changes in concomitant medications and (S)AEs will also be recorded.

03

Conditions studied

  • COVID-19
  • Cardiovascular Diseases
  • Cardiovascular Risk Factor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Males and females 18 years of age or older 2. Hospitalized for COVID-19 with the most recent test positive*; not receiving or likely to receive invasive mechanical ventilation within the next 24 hours 3. Prior history of at least one of: i) CVD [cardiovascular (CV), cerebrovascular or peripheral vascular diagnoses], ii) Age > 64, iii) Diabetes (DM), iv) Hypertension (HTN), v) Abnormal serum lipids, vi) Obesity ( > or equal 30 or waist circumference >102 cm [40"] for men and >88 cm [35"] for women), vii) Current smoker

* Must be PCR test.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have received vasopressors, extracorporeal membrane oxygenation and mechanical ventilation within last 30 days
  2. Background of cardiac transplant surgery
  3. Implanted defibrillator (ICD) in the last three months
  4. Implanted left-ventricular assist device (LVAD)
  5. Acute coronary syndrome (ACS) within 30 days
  6. Percutaneous coronary intervention (PCI) within 30 days
  7. Receiving any immuno-suppressive agent other than dexamethasone
  8. History of prolongation
  9. QTc interval > 500 msec
  10. Treated with strong inducers of or CYP2C19
  11. Chronic renal failure, determined as \< 30 ml/min
  12. Elevated (ALT) or aspartate aminotransferase (AST) > 5 times the (ULN) or ALT or AST >3x ULN plus >2x ULN
  13. Bacterial sepsis, defined as documented bacteremia at the time of presentation or other active bacterial infection
  14. Current participation in any research study involving drugs or devices with the exception of dexamethasone, remdesivir, baricitinib plus remdesivir, convalescent plasma or monoclonal antibodies against the SARS-CoV-2 virus or any other therapy approved under emergency use in the region for treatment of COVID-19
  15. Inability or unwillingness to give
  16. Ongoing drug, alcohol or cannabis abuse
  17. Women who are pregnant or breastfeeding
  18. Any factor, which would make it unlikely that the patient can comply with the study procedures
  19. \<8.5 gm/dL
  20. Leukocyte count \< 3000/ mm3
  21. \< 100,000 / mm3
  22. Current diagnosis of cancer, with the exception of non-melanoma skin cancer
  23. Showing suicidal tendency as per the Columbia-Suicide Severity Rating Scale (C-SSRS) administered at screening
  24. Any cannabinoid intake in the past month
  25. Body weight > 170 kg
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Cannabidiol, pharmaceutically produced with < 5 ppm THC

    CardiolRx

    Drug: Cannabidiol, pharmaceutically produced with < 5 ppm THC

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugCannabidiol, pharmaceutically produced with < 5 ppm THC

    Drug page: Cannabidiol

    CardiolRx 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food

    Also known as: CardiolRx

  • DrugPlacebo

    Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food

06

What researchers measure

Primary outcomes

  1. Composite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular Complications

    Proportions of patients in each group not having one of the outcome measures as described above (All-cause mortality, requirement for ICU admission and/or ventillatory support and cardiovascular complications)

    Time frame: 28 days post randomization

Secondary outcomes

  1. Ordinal Outcome Scale

    Ordinal Outcome Scale: 1. Not hospitalized and no limitations of activities. 2. Not hospitalized, with limitation of activities, home oxygen requirement, or both. 3. Hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care. 4. Hospitalized, not requiring supplemental oxygen but requiring ongoing medical care. 5. Hospitalized, requiring any supplemental oxygen. 6. Hospitalized, requiring noninvasive ventilation or use of high-flow oxygen devices. 7. Hospitalized, receiving invasive mechanical ventilation or ECMO. 8. MI or stroke diagnosed since randomization. 9. Death.

    Time frame: 28 days

07

Results

Posted Jul 25, 2025
Limitations and caveats
The study was closed prematurely because eligible patients could no longer be recruited due to vaccinations.

Participant flow

Participant flow — Overall Study
MilestoneCannabidiol, Pharmaceutically Produced With < 5 Ppm THCPlacebo
Started4545
Completed4137
Not completed48
Withdrew: Withdrawal by subject24
Withdrew: Lost to follow-up22
Withdrew: Death02

Outcome measures

PrimaryComposite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular Complications

Proportions of patients in each group not having one of the outcome measures as described above (All-cause mortality, requirement for ICU admission and/or ventillatory support and cardiovascular complications)

Time frame:
28 days post randomization
Reported as:
Count of participants · Participants
Composite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular Complications
ParticipantsCannabidiol, Pharmaceutically Produced With < 5 Ppm THCPlacebo
Composite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular Complications32
Statistical analysis
  • Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC vs Placebo · Fisher Exact · p = 0.68
SecondaryOrdinal Outcome Scale

Ordinal Outcome Scale: 1. Not hospitalized and no limitations of activities. 2. Not hospitalized, with limitation of activities, home oxygen requirement, or both. 3. Hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care. 4. Hospitalized, not requiring supplemental oxygen but requiring ongoing medical care. 5. Hospitalized, requiring any supplemental oxygen. 6. Hospitalized, requiring noninvasive ventilation or use of high-flow oxygen devices. 7. Hospitalized, receiving invasive mechanical ventilation or ECMO. 8. MI or stroke diagnosed since randomization. 9. Death.

Time frame:
28 days
Reported as:
Mean · score on a scale
Ordinal Outcome Scale
score on a scaleCannabidiol, Pharmaceutically Produced With < 5 Ppm THCPlacebo
Ordinal Outcome Scale1.40 ± 1.391.51 ± 1.85
Statistical analysis
  • Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC vs Placebo · Cochran-Mantel-Haenszel · p = 0.77CMH linear-by-linear chi-square; DF=1

Adverse events

Collected over 60 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC0/45 (0%)5/45 (11.1%)24/45 (53.3%)
Placebo2/44 (4.5%)4/44 (9.1%)23/44 (52.3%)
Most frequent serious events
Most frequent serious events
EventCannabidiol, Pharmaceutically Produced With < 5 Ppm THCPlacebo
TachycardiaCardiac disorders0/451/44
Septic ShockInfections and infestations0/451/44
ALT increaseInvestigations0/451/44
Acute kidney injuryRenal and urinary disorders0/451/44
Respiratory failureRespiratory, thoracic and mediastinal disorders1/451/44
Cardiac failureCardiac disorders1/450/44
PneumoniaInfections and infestations1/450/44
QTC segment prolongationInvestigations1/450/44
Renal impairmentRenal and urinary disorders1/450/44
Most frequent other events
Showing 10 of 61
Most frequent other events
EventCannabidiol, Pharmaceutically Produced With < 5 Ppm THCPlacebo
NauseaGastrointestinal disorders5/452/44
HeadacheNervous system disorders4/453/44
ConstipationGastrointestinal disorders2/453/44
DyspepsiaGastrointestinal disorders2/453/44
DizzinessNervous system disorders0/453/44
TachycardiaCardiac disorders0/453/44
DysgeusiaNervous system disorders3/452/44
HypertensionVascular disorders3/451/44
SomnolenceNervous system disorders1/452/44
CoughRespiratory, thoracic and mediastinal disorders0/452/44

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cannabidiol, Pharmaceutically Produced With < 5 Ppm THCPlaceboTotal
Mean60.4 ± 14.8662.0 ± 12.9561.2 ± 13.89
Sex: Female, Male
Sex: Female, Male(Participants)Cannabidiol, Pharmaceutically Produced With < 5 Ppm THCPlaceboTotal
Female192039
Male262551
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cannabidiol, Pharmaceutically Produced With < 5 Ppm THCPlaceboTotal
Hispanic or Latino424284
Not Hispanic or Latino336
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cannabidiol, Pharmaceutically Produced With < 5 Ppm THCPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American235
White282755
More than one race151530
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Cannabidiol, Pharmaceutically Produced With < 5 Ppm THCPlaceboTotal
United States252651
Brazil6410
Mexico141529
Obesity
Obesity(Participants)Cannabidiol, Pharmaceutically Produced With < 5 Ppm THCPlaceboTotal
Count of participants192342
Diabetes
Diabetes(Participants)Cannabidiol, Pharmaceutically Produced With < 5 Ppm THCPlaceboTotal
Count of participants171936
Hyperlipidemia
Hyperlipidemia(Participants)Cannabidiol, Pharmaceutically Produced With < 5 Ppm THCPlaceboTotal
Count of participants7916

1 further baseline measures are reported on the registry.

08

Study locations

20 sites
  • Valleywise Health Medical Center
    Phoenix, Arizona 85008, United States
  • JY Research Institute
    Cutler Bay, Florida 33189, United States
  • Westchester General Hospital
    Miami, Florida 33155, United States
  • University of South Florida
    Tampa, Florida 33613, United States
  • Prairie Education and Research Cooperative
    Springfield, Illinois 62769, United States
  • University of Texas Health Science Center
    San Antonio, Texas 78229, United States
  • Baylor Scott & White Health - Temple
    Temple, Texas 76508, United States
  • Science Valley Research Institute
    Campo Largo, Paraná 83606, Brazil
  • Universidade Estadual de Maringa
    Maringá, Paraná 87020-900, Brazil
  • Hospital São Lucas PUCRS
    Porto Alegre, Rio Grande do Sul 90619-900, Brazil
  • Irmandade Santa Casa de Misericórdia
    Porto Alegre, Rio Grande do Sul, Brazil
  • Núcleo de Ensino e Pesquisa do Instituto Mário Penna
    Conjunto ACM, Santa Maria 30380-472, Brazil
  • Fundação Pio XII - Hospital de Amor Barretos
    Barretos, São Paulo 14784-400, Brazil
  • IPECC-Instituto de Pesquisa Clínica de Campinas
    Campinas, São Paulo 13060-080, Brazil
  • Instituto do Coração do HCFMUSP
    Cerqueira César, São Paulo 05403-000, Brazil
  • SVRI- Irmandade de Santa Casa de Misercordia de Santos
    Jabaquara, São Paulo 1409, Brazil
  • Science Valley Research Institute
    Santo André, São Paulo 1409, Brazil
  • Fundação Faculdade Regional de Medicine de Sao Jose do Rio Preto (SJRP)
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Complexo Hospitalar de Niteroi- Centro de Pesquisa Clinica
    Rio de Janeiro, 24020, Brazil
  • TecSalud
    Monterrey, Nuevo León 64718, Mexico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data will become available once the study has been published

Supporting information: Study protocol

Time frame: Data will become available in Q4 2022

Access criteria: Access to the journal in which article has been published

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Nov 2022, 19 months.

Results were first posted in Jul 2025, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2020
First posted
Nov 4, 2020
StartActual
Apr 30, 2021
Primary completionActual
Nov 30, 2022
CompletionActual
Nov 30, 2022
Results first posted
Jul 25, 2025
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04615949
Lead sponsor
Cardiol Therapeutics Inc.
Responsible party
Sponsor
First posted
Nov 4, 2020
Start date
Apr 30, 2021
Primary completion
Nov 30, 2022
Completion
Nov 30, 2022
Results posted
Jul 25, 2025
Last update
Apr 21, 2026

Study contacts

Dennis McNamara, MD
study chair · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion